One of the most effective strategies to improve overall efficacy is to develop a bispecific antibody simultaneously targeting PD-1/PD-L1 and VEGF could potentially gain higher target binding specificity and enhanced anti-tumor activity, while also improving safety profiles (9). This evidence concerns the gene CD274 and neoplasm.